I read Vijay Pande’s piece on the A16Z blog from start to finish multiple times. It’s worth checking out if you haven’t seen it already. I have zero biochemistry background, so take most of my commentary with a reasonable grain of salt. I run a site that helps chronically ill patients aggregate their medical records and find relevant clinical […]
Kumar Thangudu
The skinny on Martin Shkreli, the acquirer of Turing Pharmaceuticals. Raise a couple of hundred million. Buy orphan drug. (Drugs with less than 3000 patients) Insurance companies +FDA won’t pay for or certify the viability of cheaper foreign generics/biosimilars. Make Insurance companies foot the bill. If the patient doesn’t have insurance, give it away for […]
Kumar Thangudu
Deeming a drug safe is much easier than deeming it effective. One thing most people don’t understand is that the hard scientific costs of drug development at a scientific level are usually millions of dollars, not billions. What happened in the late 50’s and 60’s was the birth of children with limb malformities/malformations as a […]
Kumar Thangudu